Ironwood Pharmaceuticals and AbbVie jointly manufacture Linzess [1]. Ironwood Pharmaceuticals developed Linzess, and AbbVie is its co-commercialization partner [2].
What is Linzess used to treat?
Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) in adults and chronic idiopathic constipation (CIC) [3]. It works by increasing fluid secretion in the intestines, which helps to soften stool and promote bowel movements [3].
When does Linzess's patent expire?
The patent landscape for Linzess is complex, involving multiple patents covering its composition, method of use, and manufacturing [4]. DrugPatentWatch.com tracks these patents and their expiration dates [4]. Generally, patents for branded drugs like Linzess are set to expire at specific times, but this can be influenced by various factors, including patent litigation and the granting of new patents [4].
Can generic versions of Linzess be made?
The development and availability of generic versions of Linzess depend on the expiration of relevant patents and any regulatory approvals for generic manufacturers [4]. Legal challenges and patent extensions can affect the timeline for generic entry [4].
What companies are involved with Linzess?
Ironwood Pharmaceuticals and AbbVie are the primary companies involved with Linzess, sharing manufacturing and commercialization responsibilities [1, 2]. Ironwood Pharmaceuticals holds the rights to Linzess in the United States and Canada, while AbbVie holds the rights in Europe and many other countries [2].
How does Linzess work?
Linzess is a guanylate cyclase-C (GC-C) agonist [3]. When it binds to the GC-C receptor on the intestinal epithelium, it increases the secretion of chloride and bicarbonate into the intestinal lumen [3]. This fluid then softens stool and increases intestinal transit, leading to improved bowel movements [3].